Doctolib Valuation Adjusts in Secondary Share Sale

Doctolib, the prominent European digital health platform, has experienced a significant recalibration of its valuation, with employees and early backers divesting shares valued at approximately $345 million. This secondary transaction, which welcomed new investors including Generation Investment Management, places the company's implied worth at roughly €3.6 billion. This figure represents a notable decrease from the €5.8 billion valuation established during its last primary funding round in March 2022, signaling a broader market adjustment for high-growth technology firms.

The move comes as Doctolib, founded in 2013 by CEO Stanislas Niox-Chateau, continues to expand its reach across France, Germany, and Italy. The company's platform facilitates appointment scheduling and administrative tasks for a vast network of healthcare professionals, serving tens of millions of patients. Despite the valuation adjustment, Doctolib has demonstrated robust financial performance, exceeding €400 million in annual revenue in 2024 and approaching €422 million in annual recurring revenue by the close of 2025. This financial trajectory underscores its established market position within the healthtech sector.

This secondary sale is strategically positioned as a precursor to a potential initial public offering, which Doctolib is reportedly eyeing for late 2026 or 2027. Such transactions are instrumental in providing liquidity for existing shareholders, including early investors and employees, while simultaneously offering new entrants an opportunity to gain exposure to the company ahead of a public listing. The participation of established investors like Generation Investment Management, alongside previous supporters such as Eurazeo, General Atlantic, and Accel, highlights continued confidence in the company's long-term prospects.

The valuation shift reflects a more discerning investment climate in the European private capital markets. Following a period of aggressive funding and elevated valuations, public market investors are now applying greater scrutiny, particularly to pre-profitability companies. While Doctolib has reportedly made strides toward profitability, a definitive timeline for achieving this at scale has not yet been publicly disclosed. This cautious approach from investors is a key factor influencing current deal valuations.

The healthtech sector, in particular, has seen intense investor interest, driven by the accelerating adoption of digital solutions in healthcare delivery. However, the market is now differentiating between companies with sustainable business models and those that benefited from pandemic-era tailwinds. Doctolib's substantial user base and consistent revenue growth suggest a strong foundation, even as it navigates a more challenging funding environment. The company's previous status as France's most valuable private startup, before being surpassed by AI firm Mistral AI, further contextualizes its significant market presence.

This secondary transaction provides crucial market data on how established, late-stage private companies are being valued in the current economic climate. It offers a benchmark for other healthtech firms seeking capital or preparing for liquidity events. The involvement of sustainability-focused investors like Generation Investment Management also points to a growing trend of integrating environmental, social, and governance considerations into investment theses, even within the fast-paced tech sector.